Insmed Incorporated (0JAV.L)
USD 71.8
(-4.53%)
USD 71.8
(-4.53%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 1.66 Billion USD | 5.95% |
| 2022 | 1.56 Billion USD | 88.28% |
| 2021 | 833.04 Million USD | 60.12% |
| 2020 | 520.27 Million USD | 8.25% |
| 2019 | 480.62 Million USD | 21.28% |
| 2018 | 396.29 Million USD | 292.41% |
| 2017 | 100.98 Million USD | 20.98% |
| 2016 | 83.47 Million USD | 86.08% |
| 2015 | 44.85 Million USD | 0.52% |
| 2014 | 44.62 Million USD | 34.52% |
| 2013 | 33.17 Million USD | 1.51% |
| 2012 | 32.67 Million USD | 487.12% |
| 2011 | 5.56 Million USD | 62.65% |
| 2010 | 3.42 Million USD | 23.05% |
| 2009 | 2.78 Million USD | -63.32% |
| 2008 | 7.58 Million USD | -5.38% |
| 2007 | 8.01 Million USD | -44.62% |
| 2006 | 14.46 Million USD | 17.24% |
| 2005 | 12.34 Million USD | 113.66% |
| 2004 | 5.77 Million USD | 60.8% |
| 2003 | 3.59 Million USD | -26.09% |
| 2002 | 4.86 Million USD | -59.2% |
| 2001 | 11.91 Million USD | 100.66% |
| 2000 | 5.93 Million USD | 611.8% |
| 1999 | 833.94 Thousand USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 1.77 Billion USD | 9.08% |
| 2024 Q1 | 1.62 Billion USD | -2.28% |
| 2024 Q3 | 1.56 Billion USD | -11.39% |
| 2023 FY | 1.66 Billion USD | 5.95% |
| 2023 Q3 | 1.61 Billion USD | 1.21% |
| 2023 Q2 | 1.59 Billion USD | 2.08% |
| 2023 Q1 | 1.56 Billion USD | -0.39% |
| 2023 Q4 | 1.66 Billion USD | 2.94% |
| 2022 Q2 | 1 Billion USD | -2.35% |
| 2022 Q4 | 1.56 Billion USD | 53.06% |
| 2022 Q1 | 1.03 Billion USD | 24.06% |
| 2022 FY | 1.56 Billion USD | 88.28% |
| 2022 Q3 | 1.02 Billion USD | 1.55% |
| 2021 Q1 | 490.75 Million USD | -5.67% |
| 2021 Q3 | 806.92 Million USD | 15.49% |
| 2021 Q4 | 833.04 Million USD | 3.24% |
| 2021 Q2 | 698.73 Million USD | 42.38% |
| 2021 FY | 833.04 Million USD | 60.12% |
| 2020 Q4 | 520.27 Million USD | 7.57% |
| 2020 FY | 520.27 Million USD | 8.25% |
| 2020 Q1 | 469.82 Million USD | -2.25% |
| 2020 Q2 | 480.04 Million USD | 2.18% |
| 2020 Q3 | 483.65 Million USD | 0.75% |
| 2019 FY | 480.62 Million USD | 21.28% |
| 2019 Q1 | 451.77 Million USD | 14.0% |
| 2019 Q2 | 446.21 Million USD | -1.23% |
| 2019 Q4 | 480.62 Million USD | 4.69% |
| 2019 Q3 | 459.07 Million USD | 2.88% |
| 2018 Q2 | 353.6 Million USD | 4.52% |
| 2018 FY | 396.29 Million USD | 292.41% |
| 2018 Q4 | 396.29 Million USD | 7.07% |
| 2018 Q1 | 338.29 Million USD | 234.99% |
| 2018 Q3 | 370.1 Million USD | 4.67% |
| 2017 Q4 | 100.98 Million USD | 18.95% |
| 2017 Q3 | 84.9 Million USD | 3.29% |
| 2017 Q2 | 82.19 Million USD | 4.08% |
| 2017 FY | 100.98 Million USD | 20.98% |
| 2017 Q1 | 78.97 Million USD | -5.39% |
| 2016 Q4 | 83.47 Million USD | 41.92% |
| 2016 FY | 83.47 Million USD | 86.08% |
| 2016 Q1 | 45.24 Million USD | 0.86% |
| 2016 Q2 | 49.11 Million USD | 8.56% |
| 2016 Q3 | 58.81 Million USD | 19.75% |
| 2015 Q4 | 44.85 Million USD | -4.03% |
| 2015 Q1 | 41.28 Million USD | -7.48% |
| 2015 FY | 44.85 Million USD | 0.52% |
| 2015 Q2 | 43.16 Million USD | 4.56% |
| 2015 Q3 | 46.74 Million USD | 8.28% |
| 2014 Q4 | 44.62 Million USD | 23.36% |
| 2014 Q3 | 36.17 Million USD | -6.19% |
| 2014 Q1 | 34.88 Million USD | 5.15% |
| 2014 FY | 44.62 Million USD | 34.52% |
| 2014 Q2 | 38.56 Million USD | 10.55% |
| 2013 FY | 33.17 Million USD | 1.51% |
| 2013 Q1 | 35.41 Million USD | 8.36% |
| 2013 Q2 | 33.54 Million USD | -5.28% |
| 2013 Q4 | 33.17 Million USD | 1.06% |
| 2013 Q3 | 32.82 Million USD | -2.13% |
| 2012 Q3 | 15.84 Million USD | -3.01% |
| 2012 Q2 | 16.33 Million USD | 219.12% |
| 2012 FY | 32.67 Million USD | 487.12% |
| 2012 Q1 | 5.11 Million USD | -8.03% |
| 2012 Q4 | 32.67 Million USD | 106.24% |
| 2011 Q4 | 5.56 Million USD | 49.34% |
| 2011 Q3 | 3.72 Million USD | 4.99% |
| 2011 Q2 | 3.55 Million USD | -23.92% |
| 2011 FY | 5.56 Million USD | 62.65% |
| 2011 Q1 | 4.66 Million USD | 36.35% |
| 2010 Q1 | 2.46 Million USD | -11.43% |
| 2010 FY | 3.42 Million USD | 23.05% |
| 2010 Q4 | 3.42 Million USD | 48.78% |
| 2010 Q3 | 2.3 Million USD | -23.79% |
| 2010 Q2 | 3.01 Million USD | 22.53% |
| 2009 Q3 | 3.58 Million USD | -22.36% |
| 2009 Q2 | 4.61 Million USD | -65.51% |
| 2009 Q1 | 13.38 Million USD | 76.55% |
| 2009 FY | 2.78 Million USD | -63.32% |
| 2009 Q4 | 2.78 Million USD | -22.41% |
| 2008 FY | 7.58 Million USD | -5.38% |
| 2008 Q1 | 7.82 Million USD | -2.37% |
| 2008 Q4 | 7.58 Million USD | 2.25% |
| 2008 Q3 | 7.41 Million USD | -19.94% |
| 2008 Q2 | 9.26 Million USD | 18.4% |
| 2007 Q4 | 8.01 Million USD | -1.79% |
| 2007 FY | 8.01 Million USD | -44.62% |
| 2007 Q1 | 12.01 Million USD | -16.94% |
| 2007 Q2 | 7.64 Million USD | -36.38% |
| 2007 Q3 | 8.15 Million USD | 6.71% |
| 2006 Q3 | 11.32 Million USD | 3.42% |
| 2006 Q4 | 14.46 Million USD | 27.72% |
| 2006 Q2 | 10.95 Million USD | 35.88% |
| 2006 Q1 | 8.06 Million USD | -34.68% |
| 2006 FY | 14.46 Million USD | 17.24% |
| 2005 Q2 | 24.61 Million USD | 4.42% |
| 2005 Q3 | 19.45 Million USD | -20.98% |
| 2005 FY | 12.34 Million USD | 113.66% |
| 2005 Q4 | 12.34 Million USD | -36.56% |
| 2005 Q1 | 23.57 Million USD | 308.17% |
| 2004 Q3 | 6.7 Million USD | 4.79% |
| 2004 Q1 | 3.87 Million USD | 7.93% |
| 2004 FY | 5.77 Million USD | 60.8% |
| 2004 Q4 | 5.77 Million USD | -13.79% |
| 2004 Q2 | 6.39 Million USD | 64.92% |
| 2003 Q2 | 4.48 Million USD | 8.88% |
| 2003 Q4 | 3.59 Million USD | -9.27% |
| 2003 Q3 | 3.95 Million USD | -11.75% |
| 2003 Q1 | 4.12 Million USD | -15.23% |
| 2003 FY | 3.59 Million USD | -26.09% |
| 2002 Q1 | 9.03 Million USD | -24.17% |
| 2002 Q2 | 8.67 Million USD | -3.99% |
| 2002 Q3 | 7.41 Million USD | -14.47% |
| 2002 FY | 4.86 Million USD | -59.2% |
| 2002 Q4 | 4.86 Million USD | -34.47% |
| 2001 Q4 | 11.91 Million USD | 44.41% |
| 2001 FY | 11.91 Million USD | 100.66% |
| 2001 Q1 | 6.68 Million USD | 12.69% |
| 2001 Q3 | 8.24 Million USD | -2.53% |
| 2001 Q2 | 8.46 Million USD | 26.51% |
| 2000 Q4 | 5.93 Million USD | -18.63% |
| 2000 Q3 | 7.29 Million USD | 97.54% |
| 2000 Q2 | 3.69 Million USD | 174.37% |
| 2000 FY | 5.93 Million USD | 611.8% |
| 2000 Q1 | 1.34 Million USD | 0.0% |
| 1999 FY | 833.94 Thousand USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Editas Medicine, Inc. | 150.05 Million USD | -1007.427% |
| Dynavax Technologies Corporation | 375.02 Million USD | -343.108% |
| Supernus Pharmaceuticals, Inc. | 487.46 Million USD | -240.901% |
| Perrigo Company plc | 6.04 Billion USD | 72.493% |
| Illumina, Inc. | 4.36 Billion USD | 61.939% |
| Thermo Fisher Scientific Inc. | 51.88 Billion USD | 96.797% |
| Iovance Biotherapeutics, Inc. | 195.73 Million USD | -748.972% |
| Walgreens Boots Alliance, Inc. | 68.85 Billion USD | 97.587% |
| IQVIA Holdings Inc. | 20.56 Billion USD | 91.921% |
| Heron Therapeutics, Inc. | 256.47 Million USD | -547.913% |
| Regeneron Pharmaceuticals, Inc. | 7.1 Billion USD | 76.618% |
| Unity Biotechnology, Inc. | 37.29 Million USD | -4356.076% |
| Waters Corporation | 3.47 Billion USD | 52.2% |
| Biogen Inc. | 12.04 Billion USD | 86.204% |
| Sangamo Therapeutics, Inc. | 82.43 Million USD | -1915.892% |
| Evolus, Inc. | 209.68 Million USD | -692.495% |
| Adicet Bio, Inc. | 37.12 Million USD | -4376.724% |
| Cara Therapeutics, Inc. | 68.75 Million USD | -2316.789% |
| bluebird bio, Inc. | 424.62 Million USD | -291.349% |
| Esperion Therapeutics, Inc. | 660.79 Million USD | -151.481% |
| FibroGen, Inc. | 585.72 Million USD | -183.708% |
| Agilent Technologies, Inc. | 4.91 Billion USD | 66.211% |
| Corbus Pharmaceuticals Holdings, Inc. | 35.17 Million USD | -4623.98% |
| Homology Medicines, Inc. | 118.53 Million USD | -1301.939% |
| Geron Corporation | 146.12 Million USD | -1037.203% |
| Alnylam Pharmaceuticals, Inc. | 4.05 Billion USD | 58.974% |
| Amicus Therapeutics, Inc. | 617.7 Million USD | -169.021% |
| Myriad Genetics, Inc. | 312.9 Million USD | -431.083% |
| Viking Therapeutics, Inc. | 20.07 Million USD | -8179.408% |
| Intellia Therapeutics, Inc. | 250.8 Million USD | -562.563% |
| Zoetis Inc. | 9.29 Billion USD | 82.122% |
| Abeona Therapeutics Inc. | 49.17 Million USD | -3279.209% |
| Mettler-Toledo International Inc. | 3.5 Billion USD | 52.596% |
| BioMarin Pharmaceutical Inc. | 1.89 Billion USD | 12.079% |
| Vertex Pharmaceuticals Incorporated | 5.14 Billion USD | 67.732% |
| Kala Pharmaceuticals, Inc. | 48.44 Million USD | -3330.199% |
| Ionis Pharmaceuticals, Inc. | 2.6 Billion USD | 36.169% |
| Atara Biotherapeutics, Inc. | 264.73 Million USD | -527.707% |
| Verastem, Inc. | 71.18 Million USD | -2234.424% |
| Nektar Therapeutics | 267.04 Million USD | -522.275% |
| Axsome Therapeutics, Inc. | 397.25 Million USD | -318.306% |
| Aclaris Therapeutics, Inc. | 40.22 Million USD | -4031.06% |
| Sarepta Therapeutics, Inc. | 2.4 Billion USD | 30.911% |
| OPKO Health, Inc. | 622.47 Million USD | -166.958% |
| Exelixis, Inc. | 678.44 Million USD | -144.937% |
| Neurocrine Biosciences, Inc. | 1.01 Billion USD | -63.014% |
| Corcept Therapeutics Incorporated | 114.81 Million USD | -1347.375% |
| Anavex Life Sciences Corp. | 12.53 Million USD | -13158.018% |
| uniQure N.V. | 624.01 Million USD | -166.3% |
| Imunon, Inc. | 8.53 Million USD | -19380.385% |
| Blueprint Medicines Corporation | 918.64 Million USD | -80.893% |
| Halozyme Therapeutics, Inc. | 1.64 Billion USD | -0.746% |
| Agios Pharmaceuticals, Inc. | 126.09 Million USD | -1217.822% |
| TG Therapeutics, Inc. | 169.08 Million USD | -882.796% |
| Incyte Corporation | 1.59 Billion USD | -4.364% |
| Emergent BioSolutions Inc. | 1.18 Billion USD | -40.162% |